Fulgent Genetics (FLGT) Q4 2025: $59M Customer Loss Offset by 53% AP Expansion and AI Leverage

2026-02-27 | By EarningsIQ Research

Fulgent Genetics faces a pivotal year as a $59 million customer loss is counterbalanced by a major anatomic pathology (AP, tissue-based diagnostics) acquisition and accelerating AI-driven productivity. Management’s approach to customer diversification, digital pathology, and cross-segment synergies will define the company’s trajectory as it navigates margin compression and integration risk. Investors should closely watch execution on commercial pipeline growth and AP integration, as the company pivots from customer concentration to platform scale.

Summary

• Customer Concentration Reset: A single customer’s in-house move erases $59 million in revenue, forcing a shift to diversified growth.
• AI and Digital Pathology Scale: Proprietary platforms and in-house AI modules drive operational leverage and capacity expansion.
• Acquisition Integration Critical: Success hinges on seamless Bako and StrataDX onboarding and cross-selling in AP and precision diagnostics.

Performance Analysis

Fulgent posted double-digit growth in 2025, with total revenue up 14% year-over-year to $322.7 million, but the quarter revealed a sharp inflection as the company’s largest customer began shifting significant testing volumes in-house. This customer represented $70.8 million, or 22% of 2025 revenue, and is projected to drop to $11.8 million for 2026, resulting in a $59 million revenue headwind. The impact was most acute in precision diagnostics, which saw sequential volume declines in Q4 despite 11% YoY growth. Anatomic pathology (AP) and biopharma services provided partial offset, with AP up 3% YoY and biopharma services up 32% YoY in the quarter, though both remain smaller contributors.

Gross margin pressure emerged as a direct result of the lost scale, with non-GAAP margins dropping to 41% in Q4 and forecast to dip further in the first half of 2026 before rebounding as AP scale and AI efficiencies kick in. Operating expenses spiked due to acquisition and one-time charges, driving a negative non-GAAP operating margin of -10.7%. Despite these headwinds, Fulgent exceeded non-GAAP EPS guidance for the year and ended with a robust $705.5 million cash position, providing flexibility for M&A and R&D investment.

• Customer Loss Drives Revenue Volatility: The $59 million reduction from the largest customer is only partially offset by organic growth and the pending Bako/StrataDX acquisition.
• Margin Compression in Transition: Gross margins are expected to fall up to four points in Q1 2026, with recovery hinging on AP integration and operational scale.
• Cash Resilience Despite Burn: Cash outflows are dominated by M&A, R&D, and one-time items, with core lab operations consuming modest cash even under pressure.

The next two quarters will test Fulgent’s ability to execute on its diversification and integration strategy, as the AP business is expected to grow 53% and become a larger share of the revenue mix.

Executive Commentary

Strategic Positioning

1. Customer Concentration and Revenue Diversification

Fulgent’s largest customer represented 22% of 2025 revenue, and the abrupt in-sourcing of testing exposes the company’s vulnerability to concentration risk. Management projects no single customer will exceed 10% of revenue post-acquisition, a critical milestone for long-term stability. The Bako and StrataDX deals are intended to diversify the base, expand AP offerings, and reduce future single-customer dependency.

2. AI-Enabled Operational Leverage

Investment in digital pathology and proprietary AI modules, such as Easyopath, is already delivering improved turnaround, quality, and capacity. The transition to 100% digital pathology enables remote reading, national recruitment of pathologists, and operational scale without linear headcount growth. AI modules targeting tissue detection and cancer diagnosis are expected to drive further efficiency and accuracy, with a dozen new modules planned for 2026.

3. Precision Diagnostics Pipeline and Brand Building

Fulgent’s BEACON (expanded carrier screening) and RISE (RNA-integrated whole genome sequencing) tests are gaining market share, even as legacy volume from the departing customer wanes. The company emphasizes its growing EMR connectivity, rapid turnaround, and depth of panel as differentiators. Somatic oncology (Lumera) and new regulatory approvals in New York open incremental markets and reinforce the value of the innovation pipeline.

4. Acquisition-Driven Scale in Anatomic Pathology

The pending Bako and StrataDX acquisitions are projected to add $50–$55 million in AP revenue, driving 53% YoY AP growth and nearly doubling the sales team. The integration of these platforms with Fulgent’s digital pathology tools is expected to unlock cross-selling and operational synergies, but success depends on rapid onboarding and harmonization of workflows and technology.

5. Therapeutic Development Pipeline

The clinical pipeline, including FID-07 (oncology, phase II) and FID-022 (solid tumors, phase I), is advancing on schedule, with $26 million allocated to R&D in 2026. While not yet revenue-generating, these programs provide optionality and potential long-term upside if clinical milestones are met.

Key Considerations

This quarter marks a transition from customer concentration risk to a bet on platform leverage, AI productivity, and acquisition integration. The next 12 months will reveal whether Fulgent can deliver on its promise of diversified, scalable growth while absorbing margin and cash flow volatility.

Key Considerations:

• AP Integration Pace: Rapid onboarding of Bako and StrataDX is essential to offset lost customer revenue and deliver on synergy targets.
• AI Productivity Realization: Full deployment of digital pathology and AI modules must translate into tangible margin and throughput gains.
• Precision Diagnostics Pipeline Execution: Continued BEACON and RISE adoption is needed to rebuild organic growth and validate R&D investment.
• Cash and Capital Allocation Discipline: Maintaining a strong cash position while funding R&D, acquisitions, and integration costs is critical.
• Commercial Team Expansion: Doubling the sales force, especially in AP, must drive incremental revenue without overextending fixed costs.

Risks

Execution risk is high as Fulgent must simultaneously integrate two acquisitions, absorb a major revenue loss, and deliver on AI-driven efficiency promises. Margin pressure is acute in the first half, and failure to convert pipeline or realize AP synergies could prolong cash burn. The competitive landscape in diagnostics and digital pathology is intensifying, and regulatory or reimbursement shifts could also disrupt growth plans. Management’s ability to manage scale and complexity will be tested.

Forward Outlook

For Q1 and Q2 2026, Fulgent expects:

• Revenue headwinds from customer loss, with stabilization in H2 as acquisitions ramp.
• Gross margins to decline by up to four points in Q1, then rebound to above 41% by Q4.

For full-year 2026, management guided:

• Total revenue of $350 million (8.5% YoY growth).
• AP revenue of $162 million (53% YoY growth).
• Non-GAAP EPS loss of $1.45 per share.

Management highlighted:

• The second half will benefit from full Bako/StrataDX contribution and organic pipeline growth.
• Biopharma services will decline due to longer sales cycles, but precision diagnostics pipeline remains robust.

Takeaways

Fulgent’s 2025 results set the stage for a high-stakes transition year, where platform leverage and acquisition execution will determine the company’s ability to outgrow a major customer loss and drive sustainable profitability.

• Margin and Revenue Trajectory Hinges on Integration: The speed and effectiveness of AP onboarding and AI rollout will dictate margin recovery and topline growth.
• Customer Diversification Reduces Tail Risk: Post-acquisition, no single customer will account for more than 10% of revenue, lowering future concentration risk.
• Watch for Pipeline Conversion: Investors should monitor BEACON, RISE, and Lumera adoption, as well as AP cross-sell, to gauge organic growth momentum through 2026.

Conclusion

Fulgent Genetics is navigating a critical inflection point, with a major customer loss forcing a pivot to diversified, technology-driven growth. The company’s ability to execute on AP integration, AI productivity, and pipeline expansion will be key to restoring margin strength and accelerating growth into 2027.

Industry Read-Through

Fulgent’s experience underscores the ongoing risk of customer concentration in diagnostics and the growing imperative for scale and digital transformation. The rapid adoption of digital pathology and AI modules signals a broader shift toward automation and remote diagnostics, which could reshape labor models and cost structures across the sector. The integration of AP and precision diagnostics, as well as the push for regulatory approvals in key states like New York, highlights the need for diversified offerings and national reach. Competitors and peers should watch for emerging best practices in AI-enabled workflow and cross-segment commercial execution as the industry evolves.

FLGT Healthcare Diagnostics Digital Pathology AI Anatomic Pathology Acquisition Precision Diagnostics